China Resources Medical Holdings Company Limited (1PH) - Net Assets
Based on the latest financial reports, China Resources Medical Holdings Company Limited (1PH) has net assets worth €7.89 Billion EUR (≈ $9.22 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.91 Billion ≈ $15.10 Billion USD) and total liabilities (€5.03 Billion ≈ $5.88 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check China Resources Medical Holdings Company strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.89 Billion |
| % of Total Assets | 61.08% |
| Annual Growth Rate | 4.39% |
| 5-Year Change | 15.21% |
| 10-Year Change | N/A |
| Growth Volatility | 2.57 |
China Resources Medical Holdings Company Limited - Net Assets Trend (2016–2025)
This chart illustrates how China Resources Medical Holdings Company Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see China Resources Medical Holdings Company market cap and net worth.
Annual Net Assets for China Resources Medical Holdings Company Limited (2016–2025)
The table below shows the annual net assets of China Resources Medical Holdings Company Limited from 2016 to 2025. Also explore 1PH year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €7.89 Billion ≈ $9.22 Billion |
+5.20% |
| 2024-12-31 | €7.50 Billion ≈ $8.77 Billion |
+6.92% |
| 2023-12-31 | €7.01 Billion ≈ $8.20 Billion |
+0.21% |
| 2022-12-31 | €7.00 Billion ≈ $8.18 Billion |
+2.21% |
| 2021-12-31 | €6.85 Billion ≈ $8.00 Billion |
+7.98% |
| 2020-12-31 | €6.34 Billion ≈ $7.41 Billion |
+3.26% |
| 2019-12-31 | €6.14 Billion ≈ $7.18 Billion |
+7.54% |
| 2018-12-31 | €5.71 Billion ≈ $6.68 Billion |
+1.93% |
| 2017-12-31 | €5.60 Billion ≈ $6.55 Billion |
+4.56% |
| 2016-12-31 | €5.36 Billion ≈ $6.26 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to China Resources Medical Holdings Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 326887000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.57 Billion | 39.20% |
| Other Components | €3.98 Billion | 60.80% |
| Total Equity | €6.55 Billion | 100.00% |
China Resources Medical Holdings Company Limited Competitors by Market Cap
The table below lists competitors of China Resources Medical Holdings Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Shengda Pharm
SHG:603079
|
$354.06 Million |
|
Buana Listya Tama Tbk PT
JK:BULL
|
$354.09 Million |
|
Eagle Bulk Shipping Inc
NYSE:EGLE
|
$354.29 Million |
|
National Fertilizers Limited
NSE:NFL
|
$354.35 Million |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
$353.97 Million |
|
Twin Disc Incorporated
NASDAQ:TWIN
|
$353.94 Million |
|
Taiwan Paiho Ltd
TW:9938
|
$353.91 Million |
|
YC Inox Co Ltd
TW:2034
|
$353.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Resources Medical Holdings Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,213,536,000 to 6,552,620,000, a change of 339,084,000 (5.5%).
- Net income of 495,944,000 contributed positively to equity growth.
- Dividend payments of 166,887,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €495.94 Million | +7.57% |
| Dividends Paid | €166.89 Million | -2.55% |
| Other Changes | €10.03 Million | +0.15% |
| Total Change | €- | 5.46% |
Book Value vs Market Value Analysis
This analysis compares China Resources Medical Holdings Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €4.23 | €0.26 | x |
| 2018-12-31 | €4.31 | €0.26 | x |
| 2019-12-31 | €4.55 | €0.26 | x |
| 2020-12-31 | €4.71 | €0.26 | x |
| 2021-12-31 | €4.97 | €0.26 | x |
| 2022-12-31 | €4.98 | €0.26 | x |
| 2023-12-31 | €4.48 | €0.26 | x |
| 2024-12-31 | €4.91 | €0.26 | x |
| 2025-12-31 | €5.18 | €0.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Resources Medical Holdings Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.57%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.41%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 1.97x
- Recent ROE (7.57%) is above the historical average (2.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -28.77% | -98.31% | 0.24x | 1.23x | €-2.03 Billion |
| 2017 | 7.68% | 22.42% | 0.27x | 1.26x | €-127.14 Million |
| 2018 | 7.71% | 20.92% | 0.28x | 1.31x | €-128.05 Million |
| 2019 | 6.62% | 18.48% | 0.27x | 1.33x | €-199.50 Million |
| 2020 | 5.08% | 11.27% | 0.31x | 1.47x | €-300.41 Million |
| 2021 | 6.48% | 9.40% | 0.42x | 1.62x | €-227.16 Million |
| 2022 | 2.15% | 2.47% | 0.51x | 1.72x | €-507.21 Million |
| 2023 | 4.43% | 2.55% | 0.74x | 2.35x | €-323.53 Million |
| 2024 | 9.11% | 5.74% | 0.74x | 2.14x | €-55.48 Million |
| 2025 | 7.57% | 5.41% | 0.71x | 1.97x | €-159.32 Million |
Industry Comparison
This section compares China Resources Medical Holdings Company Limited's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $5,461,579,742
- Average return on equity (ROE) among peers: -81.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Resources Medical Holdings Company Limited (1PH) | €7.89 Billion | -28.77% | 0.64x | $354.05 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $-186.42 Million | 0.00% | 0.00x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $8.75 Billion | 3.88% | 0.47x | $582.53 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.31 Billion | 5.33% | 0.71x | $21.65 Million |
| HYGEIA HC HLDGS DL-00001 (50I) | $4.48 Billion | 9.86% | 0.49x | $12.13K |
| COMPASS PATHW SP.ADR (5Y6) | $-52.85 Million | 0.00% | 0.00x | $657.30 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $20.01 Billion | 24.68% | 0.21x | $58.44K |
| Eifelhöhen-Klinik AG (EIF) | $14.93 Million | -9.50% | 3.71x | $10.05 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $14.83 Billion | 3.37% | 1.29x | $10.91 Billion |
About China Resources Medical Holdings Company Limited
China Resources Medical Holdings Company Limited, an investment holding company, provides general healthcare, hospital management, and other hospital-related services in the People's Republic of China. It operates through two segments Hospital and Other Business. The Hospital segment offers out-patient and in-patient business corresponding to self-owned hospitals. The Other Business segment offer… Read more